Viridian Therapeutics Secures U.S. FDA Approval for Lumvoa™ for TED

In June 2026, Viridian Therapeutics, Inc. received U.S. FDA approval for Lumvoa™ (veligrotug-vvze) to treat thyroid eye disease (TED). TED is a rare and debilitating autoimmune condition marked by tissue remodeling and inflammation that leads to vision impairment, pain, proptosis, and diplopia.

From Founder’s Vision to Investable Venture

Viridian has received FDA approval for Lumvoa, marking the company's first medicine and a significant advancement in the treatment of TED. Steve Mahoney, Viridian's CEO, emphasized the importance of this milestone and the preparation of their cross-functional teams. Dr. Michael Yen pointed out the drug's effectiveness in both active and chronic TED, noting improvements in key patient outcomes. Christine Gustafson of TED Community Organization expressed optimism about this new treatment option with significantly benefit patients.

Lumvoa will launch immediately, with prescriptions available to physicians. Viridian is committed to ensuring patient access to Lumvoa through its ViridianCares™ program, which provides support for insurance coverage and financial assistance.

The FDA approved Lumvoa based on the THRIVE and THRIVE-2 clinical trials, which demonstrated meaningful improvements in TED symptoms after just three weeks of treatment. Lumvoa is the first TED treatment to show significant effects on both proptosis and diplopia in both active and chronic cases, having received Breakthrough Therapy Designation and Priority Review from the FDA.

What You Need to Know Before You Begin

Lumvoa is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. Lumvoa (500 mg) is an injection for infusion.

• Infusion Reactions: Approximately 9% of patients treated with Lumvoa experience mild to moderate infusion reactions, including fever, chills, fatigue, headaches, and transient blood pressure increases. Managing these reactions generally involves administering standard medications or slowing the infusion rate.
• Inflammatory Bowel Disease: Lumvoa may trigger or worsen IBD, even in patients without a prior diagnosis. You should continuously monitor all patients for IBD symptoms; if any IBD is suspected during treatment, discontinue Lumvoa.
• Hyperglycemia: Lumvoa can cause elevated blood sugar, affecting 12% of patients in clinical trials, particularly those with preexisting diabetes or impaired glucose tolerance. Healthcare providers must assess and monitor blood glucose levels during and after infusions, ensuring appropriate glycemic control is maintained throughout treatment.
• Hearing Impairment Including Hearing Loss: Lumvoa may trigger hearing impairment, so assess patients’ hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.
• Most Common Adverse Events: Most common adverse reactions are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, increased blood creatine phosphokinase, dry skin, and hypertension.
• Females of Reproductive Potential: Appropriate forms of contraception should be implemented before initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Impact on the Healthcare Industry

This approval makes a positive impact on the healthcare industry by facilitating the first approved treatment labeled for both active and chronic stages of the disease and lowering the burden of prolonged therapies by inducing rapid proptosis and diplopia gains.

Lumvoa offers a required therapeutic alternative in the insulin-like growth factor-1 receptor, leading to market competition and pricing control to increase patient access. By proving statistically significant efficacy expands the addressable patient pool beyond acute inflammatory phases. Lumvoa stands out as the first approved product in its class with significant effect and enhanced clinical outcomes.

Lumvoa addresses industry limitations by offering effective treatment for both active and chronic TED by solving the chronic treatment gap, with data showing significant proptosis reduction within three weeks through a rapid, 5-infusion regimen over 12 weeks. Furthermore, the therapy overcomes access barriers through the comprehensive ViridianCares program by offering financial and insurance support.

Impact of the Oculoplastic Surgery Industry

The global oculoplastic surgery market size was estimated at USD 9.80 billion in 2025 and is predicted to increase from USD 10.46 billion in 2026 to approximately USD 18.74 billion by 2035, expanding at a CAGR of 6.70% from 2026 to 2035.

According to Precedence Research, this approval is transforming the market by offering the first targeted biologic labeled for both active and chronic TED. It overcomes industry limitations by providing rapid proptosis reduction and diplopia resolution in just five IV infusions and bridges active inflammation and surgical intervention for chronic patients.

The Lumvoa™ approval not only expands the oculoplastic surgery toolkit by providing a first-in-class, IGF-1R inhibitor treatment suitable for both active and chronic TED, allowing for the effective non-surgical management of proptosis and diplopia. By reducing orbital inflammation and vascularity, this therapy provides a non-surgical alternative to invasive orbital decompression surgeries.

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative medicines for autoimmune and rare diseases by leveraging antibody discovery and protein engineering, which prioritize clinical efficacy, safety, and convenient administration.

The company’s pipeline features FDA-approved Lumvoa™ for Thyroid Eye Disease, along with advancing subcutaneous options like Elegrobart and a portfolio of FcRn inhibitors. The company is primarily focusing on improving patient outcomes in rare autoimmune diseases by developing convenient, durable treatments for high unmet demand within specialized ecosystems.